Literature DB >> 30644648

Genetic determinants of acute asthma therapy response in children with moderate-to-severe asthma exacerbations.

Sze Man Tse1,2, Maja Krajinovic2, Bhupendrasinh F Chauhan3,4, Roger Zemek5,6, Jocelyn Gravel1,2, Dominic Chalut7, Naveen Poonai8, Caroline Quach2,9, Sophie Laberge1,2, Francine M Ducharme1,2,10.   

Abstract

BACKGROUND: We documented inter-individual variability in the response to acute asthma therapy in children, attributed in part to five clinical factors (oxygen saturation, asthma severity score, virus detection, fever, symptoms between exacerbations; DOORWAY study). The contribution of genetic determinants of failure of acute asthma management have not been elucidated.
OBJECTIVE: We aim to determine single nucleotide polymorphisms (SNP) associated with emergency department (ED) management failure in children.
METHODS: A prospective cohort of 591 Caucasian children aged 1-17 years with moderate-to-severe asthma managed with standardized protocol were included. We examined 53 SNPs previously associated with asthma development, phenotypes, or bronchodilator or corticosteroids response. Associations between SNPs and management failure (hospitalization, active asthma management ≥8 h in ED, or a return visit within 72 h for one of two previous criteria) were examined using logistic regression, adjusting for the five clinical predictors of management failure.
RESULTS: Four-hundred ninety-one subjects had complete clinical data and usable DNA samples. While controlling for clinical determinants, rs295137 in SPATS2L (OR = 1.77, 95%CI: 1.17, 2.68) was significantly associated with increased odds of ED management failure. Two SNPs in IL33 were associated with decreased odds of ED management failure: rs7037276 (OR = 0.55, 95%CI: 0.33, 0.90), and rs1342326 (OR = 0.52, 95%CI: 0.32, 0.86). The addition of these three SNPs to the clinical predictors significantly improved the model's predictive performance (P < 0.0004).
CONCLUSION: Three SNPs were significantly associated with ED management failure in addition to clinical predictors, contributing to inter-individual variability. None has been previously associated with treatment response to acute asthma management.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  bronchodilator; emergency department; oral corticosteroids; pharmacogenetics; treatment response

Mesh:

Substances:

Year:  2019        PMID: 30644648     DOI: 10.1002/ppul.24247

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  4 in total

Review 1.  Single Nucleotide Polymorphisms (SNPs) in PRKG1 & SPATA13-AS1 are associated with bronchodilator response: a pilot study during acute asthma exacerbations in African American children.

Authors:  Jennifer N Fishe; Guillaume Labilloy; Rebecca Higley; Deirdre Casey; Amber Ginn; Brett Baskovich; Kathryn V Blake
Journal:  Pharmacogenet Genomics       Date:  2021-09-01       Impact factor: 2.000

2.  Severe childhood asthma exacerbations: Is treatment response variability in the genes?

Authors:  Monica Tang; Kanecia O Zimmerman; Jason E Lang
Journal:  Pediatr Pulmonol       Date:  2019-03-13

Review 3.  The Role of Airway Epithelial Cell Alarmins in Asthma.

Authors:  Christiane E Whetstone; Maral Ranjbar; Hafsa Omer; Ruth P Cusack; Gail M Gauvreau
Journal:  Cells       Date:  2022-03-24       Impact factor: 6.600

4.  Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank.

Authors:  Alexander G Mathioudakis; Michael Miligkos; Cristina Boccabella; Gioulinta S Alimani; Adnan Custovic; A Deschildre; Francine Monique Ducharme; Omer Kalayci; Clare Murray; Antonio Nieto Garcia; Wanda Phipatanakul; David Price; Aziz Sheikh; Ioana Octavia Agache; Leonard Bacharier; Apostolos Beloukas; Andrew Bentley; Matteo Bonini; Jose A Castro-Rodriguez; Giuseppe De Carlo; Timothy Craig; Zuzana Diamant; Wojciech Feleszko; Tim Felton; James E Gern; Jonathan Grigg; Gunilla Hedlin; Elham M Hossny; Despo Ierodiakonou; Tuomas Jartti; Alan Kaplan; Robert F Lemanske; Peter N Le Souëf; Mika J Mäkelä; Georgios A Mathioudakis; Paolo Matricardi; Marina Mitrogiorgou; Mario Morais-Almeida; Karthik Nagaraju; Effie Papageorgiou; Helena Pité; Paulo M C Pitrez; Petr Pohunek; Graham Roberts; Ioanna Tsiligianni; Stephen Turner; Susanne Vijverberg; Tonya A Winders; Gary Wk Wong; Paraskevi Xepapadaki; Heather J Zar; Nikolaos G Papadopoulos
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.